Daraxonrasib Cracks KRAS but Exposes Precision Oncology's Next Hurdles in Pancreatic Cancer

The Revolution Medicines Phase 3 trial of daraxonrasib (n=500 patients with previously treated metastatic pancreatic ductal adenocarcinoma) demonstrated a near-doubling of median overall survival from 6.7 to 13.2 months versus chemotherapy, with a 60% reduction in death risk. This randomized study, presented May 31 2026, employed an oral agent that hijacks cyclophilin A to indirectly disable mutant KRAS rather than binding the notoriously flat protein surface directly. While the source frames this as the end of the undruggable era, it underplays that the cohort was limited to second-line or later patients and that grade 3+ rash occurred in over 86% of participants, though treatment discontinuation rates remained lower than with chemo. The approach builds on earlier KRAS G12C inhibitors such as sotorasib (CodeBreaK 100, n=126 in lung cancer, approved 2021) yet extends coverage to the broader KRAS mutations dominant in pancreatic disease. A critical gap in coverage is the absence of first-line data and biomarker-stratified outcomes, echoing limitations seen in the 2023 NEJM review of KRAS targeting where resistance via secondary mutations rapidly emerges. Synthesizing with the 2024 Cancer Discovery paper on cyclophilin A-KRAS complexes reveals daraxonrasib exploits a protein-folding dependency that may prove synthetically lethal only in high-KRAS contexts, suggesting future combinations with MEK or CDK4/6 inhibitors could further extend benefit. Regulatory filing is imminent, but real-world adoption will hinge on managing dermatologic toxicities and validating activity in earlier-stage disease where screening advances remain absent.